EYAS Focus, ADHD 예측 디지털 치료제

ADHD treatment primarily relies on medication and counseling, but it is difficult to grasp individual symptom patterns in real-time or predict them in advance, often resulting in uniform responses.

Parents or teachers may find it difficult to recognize signs of worsening symptoms, leading to missed treatment opportunities. Furthermore, existing treatment apps tend to focus on game-like training, lacking a preventive perspective.

EYAS Focus collects patient's daily behavior data (mobile app activity, wearable concentration metrics, etc.) and uses AI to predict patterns of inattention/hyperactivity for a certain period in the future.

This allows for proactive intervention before problems occur (e.g., providing breathing exercises via notifications, advising parents to be cautious in specific situations). Unlike existing DTx solutions that respond after symptoms appear, it enables personalized treatment plans through predictive care.

In addition, the remote monitoring function allows doctors and parents to share the patient's condition in real-time and provide non-face-to-face counseling interventions when necessary. Proactive management through predictive algorithms is the biggest differentiator.

Hospitals and clinics (B2B) treating children with ADHD will be the first to adopt and prescribe it to patients.

Subsequently, parents and guardians (B2C) may use it in the form of a paid app subscription. There is also the possibility of schools or educational authorities using it as a concentration enhancement program.

In the digital therapeutics market, similar concepts can be applied to autism spectrum disorder, mild cognitive impairment, etc., in addition to ADHD.

If the Korean startup receives regulatory approvals such as from the US FDA, it will also seek global expansion. However, it must overcome high hurdles such as clinical trials and adoption by healthcare professionals, and improve the perception of effectiveness compared to pharmaceuticals.

It received positive evaluations in terms of idea and social value. News of the Korea CES award also highlighted the point that "it combines treatment and prevention with a predictive model," attracting attention.

However, due to the nature of digital therapeutics, commercialization may be difficult if regulatory approval and medical evidence are insufficient, so experts point out the need to accumulate clinical data. Although it is considered innovative at CES, the atmosphere in the market is that it is still in the verification stage.